F-1/A: Anew Health IPO: Hong Kong Pain Management Provider Faces Going Concern

Anew Health Limited, a Hong Kong-based pain management and health services provider, is launching an initial public offering on Nasdaq amidst a significant drop in net income and auditor concerns about its ability to continue as a going concern.

Summary

• Anew Health Limited, incorporated in the Cayman Islands, operates its pain management and health services primarily through its Hong Kong subsidiaries, VG Zenith and Victor Zenith, under the ANKH brand.
• The company offers non-surgical, non-invasive, and non-pharmacological pain management and functional enhancement therapies, combining Traditional Chinese Medicine (TCM) wisdom with energy-based treatment devices.
• Anew Health also sells private-label topical use and dietary supplement products under brands like ANKH Skin Power, 30s Ice & Warm Rescue, Super 17 Probiotics, 40+ Knee Expert, A Plus Joint Expert, and Day Day Detox.
• The company operates three service centers in prime Hong Kong commercial buildings, equipped with 371 treatment devices sourced internationally.
• For the year ended March 31, 2025, total revenue was approximately US$40.0 million, a 1.9% decrease from US$40.8 million in 2024.
• Net income for the year ended March 31, 2025, was approximately US$5.5 million, a significant 53% decrease from US$11.7 million in 2024.
• The decrease in net income is attributed to increased cost of revenue (up US$1.9 million), marketing expenses (up US$1.1 million), and general and administrative expenses (up US$3.6 million).
• The company served 10,039 clients in FY2025, up from 8,692 in FY2024, with average annual spending per client increasing by 3.2% to US$6,478.
• Anew Health had a working capital deficit of US$7,827,815 as of March 31, 2025, and US$7,765,739 as of March 31, 2024, leading its auditor to express substantial doubt about its ability to continue as a going concern.
• The company plans to offer 1,800,000 Ordinary Shares in its initial public offering at an estimated price between US$4.00 and US$6.00 per share, seeking to list on the Nasdaq Capital Market under the symbol AVG.
• Net proceeds from the IPO are estimated at US$4.75 million (at US$4.00/share) and will be allocated to R&D, new service centers in Hong Kong and internationally, IT upgrades, and general working capital.

Sentiment

Score: 4

Explanation: While the company has a recognized brand, clear growth strategies, and operates in a growing market, the significant decline in net income and the auditor's 'going concern' warning present substantial financial instability. The IPO is critical for addressing these issues and funding future growth, but the underlying financial performance is a major concern.

Positives

• The ANKH brand is well-recognized and trusted in Hong Kong, evidenced by awards such as 'The Most Trusted Health Brand Award among Healthcare Workers' (2021) and 'The Most Reliable Pain Treatment Group in Asia Pacific' (2022).
• The company's RDS+ (Restore, Detox, and Strengthen) approach combines Traditional Chinese Medicine wisdom with modern energy-based treatment devices, offering non-surgical, non-invasive, and non-pharmacological therapies.
• An internal customer survey showed high satisfaction rates: 81.7% with services, 87.8% with therapist treatment, and 69.4% reported pain reduction/relief.
• The company has a broad range of treatment procedures utilizing 371 energy-based treatment devices sourced internationally, carrying certifications like CE, ISO, or GMP.
• An experienced senior management team, including founders Mr. Ka Wai Victor Mo and Ms. Sum Lok Cheung, with over 16 years in the industry, supported by qualified professionals (physiotherapists, nutritionists, Chinese Medicine Practitioners).
• Rigorous service standards and a well-established quality control and training system contribute to high customer satisfaction and a low refund rate (0.86% of contracted sales in FY2025).
• The non-pharmacological pain management market in Hong Kong is growing, driven by an aging population, increasing health awareness, and post-COVID-19 conditions, presenting significant opportunities.
• The company is expanding its network with a new 17,130 sq. ft. service center in Causeway Bay, Hong Kong, opened in June 2025, and plans for international expansion into markets like Singapore, Malaysia, Japan, South Korea, Canada, and the United States.
• Plans to establish a specialized R&D department in Q1 2025 to develop energy-based treatment devices for professional use and portable at-home devices for the consumer retail market.

Negatives

• The company had a working capital deficit of US$7,827,815 as of March 31, 2025, and US$7,765,739 as of March 31, 2024, raising substantial doubt about its ability to continue as a going concern.
• Net income decreased significantly by 53% from US$11.7 million in FY2024 to US$5.5 million in FY2025.
• Total revenue slightly decreased by 1.9% from US$40.8 million in FY2024 to US$40.0 million in FY2025.
• Increased cost of revenue (up 16.8% to US$13.2 million in FY2025) primarily due to higher personnel costs and increased headcount.
• General and administrative expenses increased by 46.8% to US$11.3 million in FY2025, driven by senior management compensation, a one-off discretionary bonus of US$1.28 million, and costs associated with opening a new treatment center.
• The company relies on a single geographical market (Hong Kong), making it vulnerable to adverse economic, social, and political conditions in the region.
• Management team lacks experience in managing a U.S. public company and complying with associated laws and regulations.
• The company does not maintain product liability insurance, exposing it to substantial financial and reputational damage from potential claims.
• Intense competition in the pain management and wellness industry, including from traditional healthcare providers, could lead to market share loss and reduced profitability.

Risks

• The working capital deficit as of March 31, 2025 and 2024 raises substantial doubt about the company's ability to continue as a going concern.
• Significant variability in operating results due to increased operating expenses and cost of revenue could adversely affect profitability.
• Unfavorable publicity or consumer perception regarding treatment safety, efficacy, or quality could negatively affect demand for services and products.
• Exposure to customer complaints, claims, and legal proceedings, which could result in significant costs and damage brand image and reputation.
• Failure to maintain the quality of equipment, treatment devices, supplies, topical use, and dietary supplement products could lead to liabilities and reputational damage.
• Reliance on third-party suppliers and manufacturers, including limited source suppliers, for products and treatment devices, poses risks of supply disruption, increased costs, or quality issues.
• Lack of long-term supply agreements with treatment device suppliers could lead to supply decreases, cost increases, or quality deterioration.
• Inherent risks relating to product liability claims or product recalls, which could cause significant expenses and damages, especially without product liability insurance.
• Inability to hire and retain qualified personnel, particularly consultants and therapists, could adversely affect service quality, brand image, and business strategy.
• Intense competition from new and existing competitors could lead to loss of market share and reduced profitability.
• If the market for products and services does not continue to grow as expected, business, financial condition, and operating results may be adversely affected.
• Reliance on a single geographical market (Hong Kong) exposes the company to adverse economic, social, and political conditions.
• Introduction of disruptive technological breakthroughs (energy-based, pharmaceutical, or other) could present challenges and make current products/services obsolete.
• Newly opened and acquired service centers may not achieve anticipated operating results, materially affecting overall results.
• Dependence on the continued services of certain key personnel; loss of their services would greatly harm the business.
• Management team lacks experience in managing a U.S. public company and complying with applicable laws, potentially affecting business and financial results.
• Failure to effectively maintain, promote, and enhance the ANKH brand in a cost-effective manner could harm business and competitive advantage.
• Substantial increases in rent or non-renewal of lease agreements could affect operations and financial condition.
• Cybersecurity risks, breaches, and other disruptions could compromise customer data, damage reputation, and expose the company to liability.
• Occurrence of force majeure events, natural disasters, pandemic outbreaks, terrorist acts, and global political events could disrupt operations and financial performance.
• Business involves significant risks and uncertainties that may not be covered by insurance.
• PRC government may exercise significant direct oversight and discretion over Hong Kong operations, potentially changing operations or share value.
• Uncertainties regarding future PRC approvals for U.S. listings and data security regulations could hinder offerings or devalue shares.
• Enforcement of laws and regulations in the PRC and Hong Kong can change quickly, limiting legal protections.
• The Hong Kong National Security Law could impact Hong Kong subsidiaries and business operations.
• Political risks associated with conducting business in Hong Kong, including potential changes in autonomy.
• Changes in currency conversion rates between HKD and USD may affect investment value.
• Corporate actions will be substantially controlled by AW Ocean Limited (96.53% voting power), potentially depriving other shareholders of a premium.
• Reliance on dividends from subsidiaries to fund cash and financing requirements; future PRC government interventions could restrict cash transfers out of Hong Kong.
• Enforcement of foreign civil liabilities in the Cayman Islands and Hong Kong is subject to certain conditions, making U.S. judgments difficult to enforce.
• Difficulties in protecting interests and limited ability to protect rights through U.S. courts due to Cayman Islands incorporation.
• Ordinary Shares may be prohibited from trading on a national exchange under the Holding Foreign Companies Accountable Act (HFCAA) if the PCAOB cannot inspect the auditor for two consecutive years.
• No public market for Ordinary Shares prior to this offering; a liquid public market may not develop, and shares may not be resold at or above the IPO price.
• Extreme stock price volatility unrelated to operating performance, financial condition, or prospects, making it difficult to assess share value.
• Ordinary Shares may be thinly traded, limiting liquidity and ability to sell shares.
• Investors purchasing in this offering will incur immediate and substantial dilution in the book value of their shares.
• Sale or availability for sale of substantial amounts of Ordinary Shares in the public market could adversely affect the market price.
• Lack of research or negative reports from securities or industry analysts could cause share price and trading volume to decline.
• Broad discretion in the use of net proceeds from the offering, which may not be used effectively.
• Nasdaq may apply additional and more stringent criteria for initial and continued listing due to small public offering size and high insider ownership.
• Inability to satisfy Nasdaq Capital Market listing requirements could lead to delisting.
• As an emerging growth company, reduced disclosure requirements may make Ordinary Shares less attractive to investors.
• As a foreign private issuer, exemption from certain U.S. domestic public company provisions may afford less protection to shareholders.
• Reliance on Cayman Islands corporate governance practices may afford less protection than full compliance with Nasdaq standards.
• Loss of foreign private issuer status in the future could result in significant additional costs and expenses.
• Increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• Reliance on price appreciation of Ordinary Shares for investment return, as dividend distribution is at the board's discretion and not planned for the foreseeable future.
• Potential classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to significant adverse tax consequences for U.S. investors.

Future Outlook

The company plans to drive organic growth by expanding its customer base and service center network in Hong Kong, enhancing brand awareness, and strategically expanding into selected global markets (Singapore, Malaysia, Japan, South Korea, Canada, and the United States). It intends to maintain and enhance the professional expertise of its frontline staff through continuous training and broaden its variety of treatment services and product offerings, including diversifying topical use and dietary supplement product lines for retail and online sales. A significant focus is on substantially enhancing research and development capabilities by establishing a specialized R&D department in Q1 2025 to develop energy-based treatment devices for professional use and portable at-home devices for the consumer retail market, with prototypes expected in early 2026 and market readiness by end of 2026.

Management Comments

• "ANKH, stands for A New Key to Health, testifying our aspiration to be a health brand not only for alleviating physical pain but also for allowing individuals to emanate joy, health, and vitality from within and throughout."
• "We believe that our professional services, proven approach to pain management, and capability to offer a broad range of treatment services and products have enabled us to offer our clients distinguished experience at our service centers."
• "We believe that our current cash and cash equivalents, anticipated cash flow from operations, available credit facilities, and the proceeds from this offering will be sufficient to meet our anticipated cash needs, including our cash needs for working capital and capital expenditures, for at least the next 12 months from the date of this prospectus."

Industry Context

The Hong Kong pain management market is experiencing growth, driven by a rapidly aging population and an increasing prevalence of musculoskeletal conditions like back and neck pain, and osteoarthritis. There's a rising demand for non-pharmacological pain management services due to concerns about opioid addiction and long-term medicine side effects, leading consumers to seek individualized and holistic approaches. The market is also influenced by post-COVID-19 conditions, which often include chronic pain symptoms. The non-pharmacological pain management market in Hong Kong is projected to grow from approximately HKD 6,674 million in 2023 to HKD 7,882 million in 2025 (CAGR of 8.7%). The industry is fragmented and highly competitive, with increasing regulatory scrutiny on selling practices, which may benefit larger, reputable providers. Technological innovations and advanced therapies are also shaping the market.

Comparison to Industry Standards

• Ranked no.3 in terms of average spending per customer among non-pharmacological pain management service providers in Hong Kong.
• Ranked no.4 in customer experience trails among non-pharmacological pain management service providers in Hong Kong.
• Competes with established local brands such as NYMG Pain Center (25 branches), New Hope Medical (2 branches), Hong Kong Medical Pain Management Association (2 branches), and HK Pain Tech Institute (5 branches).
• The company's average annual spending per client of US$6,478 in FY2025 is within the premium segment, where high-income consumers in Hong Kong spent an average of HK$49,124 (approx. US$6,300) in 2024.
• The company's non-pharmacological approach aligns with the growing industry trend of consumers seeking alternatives to traditional pharmaceutical pain relief due to concerns about side effects and addiction.

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of the prospectus, the company has not been involved in any material legal proceedings, investigations, or claims, nor is it aware of any pending or threatened litigation, arbitration, or other claims that would have a material adverse impact on its operations, financial position, and reputation.

Related Party Transactions

• Mr. Ka Wai Victor Mo, a director and ultimate shareholder, had US$1,073,723 due from him as of March 31, 2024, in the form of an unsecured, interest-free personal loan for investment purposes, which was fully repaid in cash on November 7, 2024.
• As of March 31, 2025, US$139,968 was due to Mr. Ka Wai Victor Mo, representing funds advanced by him to VG Zenith for operational expenses; this advance is unsecured, interest-free, and has no specific repayment terms.
• Salaries paid by operating subsidiaries to Mr. Ka Wai Victor Mo amounted to US$2,526,629 in FY2025 and US$563,863 in FY2024.
• Salaries paid by operating subsidiaries to Ms. Sum Lok Cheung (Mr. Mo's spouse and a director) amounted to US$603,105 in FY2025 and US$236,689 in FY2024.

Stakeholder Impact

• Shareholders face significant risks including dilution from the IPO, potential loss of investment due to the 'going concern' uncertainty, and reliance on the controlling shareholder's decisions.
• Employees benefit from increased headcount and a one-off discretionary bonus paid to senior management, but also face intense competition for qualified personnel.
• Customers may benefit from expanded service centers and new product offerings, but could be impacted by any decline in service quality or adverse publicity.
• Suppliers face risks related to the company's financial stability and reliance on ad hoc purchase orders rather than long-term contracts.
• Creditors face risks due to the company's working capital deficit and the 'going concern' warning.

Next Steps

• Listing Ordinary Shares on the Nasdaq Capital Market under the symbol AVG.
• Establishing a new service center in Hong Kong (Causeway Bay center opened in June 2025).
• Strategically expanding market coverage into selected global markets (e.g., Singapore, Malaysia, Japan, South Korea, Canada, United States).
• Maintaining and enhancing the professional expertise of frontline staff through ongoing training.
• Developing and broadening the variety of treatment services and product offerings, including diversifying topical use and dietary supplement product lines.
• Establishing a specialized Research and Development department in Q1 2025.
• Developing and commercializing energy-based treatment devices for professional use (prototype by early 2026, market ready by end of 2026).
• Developing and commercializing portable energy-based at-home treatment devices for the consumer retail market.

Key Dates

Recommendation

The company presents a mixed financial picture with a significant decline in net income and a 'going concern' warning from its auditor, indicating substantial financial risk. However, it operates in a growing market, has a recognized brand, and has outlined clear strategies for expansion and R&D, which the IPO proceeds are intended to fund. A 'hold' recommendation is appropriate as the investment carries high risk due to current financial challenges, but also potential for recovery and growth if the company successfully executes its strategies and addresses its liquidity issues. Investors should closely monitor the company's financial performance, execution of its growth plans, and resolution of the 'going concern' matter.

Keywords

Pain Management, Health Services, Traditional Chinese Medicine, TCM, Energy-based Treatment, Hong Kong, IPO, Nasdaq, Healthcare, Wellness, Non-pharmacological, Dietary Supplements, Topical Products, Medical Devices, Corporate Governance, SEC Filing, F-1/A, Going Concern, Market Expansion, R&D